GO:1900168 positive regulation of glial cell-derived neurotrophic factor production: Neurotrophic Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900168 describes any biological process that activates or increases the frequency, rate or extent of glial cell-derived neurotrophic factor (GDNF) production.
• GDNF production is regulated at transcriptional and translational levels, partly through its 5'-untranslated region.
• GDNF is induced in the brain after ischemic injury, including transient forebrain ischemia in rats.
• Pharmacological and stimulation-based interventions can elevate GDNF levels and produce neuroprotective or motor-recovery effects in animal models [2, 6].
• GDNF also modulates microglial activities, linking this GO term to neuroinflammatory regulation.
• Research on GO:1900168 relies on gene expression assays, CRISPR models, and neurotrophic factor quantification in vitro and in vivo [3, 5, 8].
Description
GO:1900168, positive regulation of glial cell-derived neurotrophic factor production, is a biological process term that captures any mechanism that activates or increases the frequency, rate or extent of glial cell-derived neurotrophic factor (GDNF) production. GDNF is a potent neurotrophic factor that supports the survival and function of dopaminergic and motor neurons, and its production is tightly controlled in the nervous system [4, 6]. Understanding how GDNF production is positively regulated is therefore central to neurobiology, neuroprotection, and regenerative medicine. The term encompasses both transcriptional and translational control mechanisms, as shown by studies on the GDNF gene's 5'-untranslated region, which regulates expression at multiple levels. Experimentally, GDNF production can be enhanced by pharmacological agents such as catalpol, by electrical stimulation paradigms like transcranial alternating current stimulation, and by viral vector-based expression systems [2, 3, 6]. These findings demonstrate that GO:1900168 is not a passive annotation but a dynamic process with clear experimental tractability. For researchers, GO:1900168 provides a standardized framework to annotate and compare interventions that raise GDNF levels, whether in the context of Parkinson's disease models, ischemic injury, or peripheral nerve reinnervation [2, 4, 8].
positive regulation of glial cell-derived neurotrophic factor production At A Glance
| GO ID | GO:1900168 |
|---|---|
| GO term | positive regulation of glial cell-derived neurotrophic factor production |
| Ontology | biological_process |
| Definition | Any process that activates or increases the frequency, rate or extent of glial cell-derived neurotrophic factor production. |
| Synonym | activation of glial cell line-derived neurotrophic factor secretion; positive regulation of GDNF production; positive regulation of glial cell-derived neurotrophic factor secretion; positive regulation of glial cell line-derived neurotrophic factor secretion |
| Major function | Upregulation of GDNF synthesis and/or secretion, supporting neuronal survival, differentiation, and neuroprotection. |
| Regulatory level | Transcriptional and translational control, as shown for the GDNF 5'-untranslated region. |
| Physiological context | Induced after ischemic injury in the brain and involved in microglial regulation. |
| Experimental modulation | Enhanced by catalpol, transcranial alternating current stimulation, and AAV-based Tet-on systems [2, 3, 6]. |
What Is GO:1900168?
In our own words, GO:1900168 refers to any biological process that turns on or ramps up the production of glial cell-derived neurotrophic factor (GDNF). It covers the steps that increase the frequency, rate, or extent of GDNF synthesis, including transcriptional activation, enhanced mRNA stability or translation, and increased secretion of the factor. It is a positive regulatory process, meaning it is defined by its ability to elevate GDNF output rather than by a single molecular mechanism.
Why Is positive regulation of glial cell-derived neurotrophic factor production Important in Cell Biology?
GO:1900168 matters because GDNF is one of the most potent survival factors for dopaminergic and motor neurons, and increasing its production is a validated strategy for neuroprotection and functional recovery in preclinical models. The term provides a precise annotation target for studies that aim to boost GDNF levels, whether through drugs, electrical stimulation, or gene therapy, and it links those interventions to a defined biological outcome [2, 3, 6]. Because GDNF production is controlled at both transcriptional and translational levels, understanding positive regulation of this process can reveal new therapeutic entry points for Parkinson's disease, ischemic injury, and peripheral nerve repair [2, 4, 8].
• GDNF is a key neurotrophic factor for midbrain dopaminergic neurons, which degenerate in Parkinson's disease [2, 6].
• Positive regulation of GDNF production is induced after transient forebrain ischemia, suggesting an endogenous neuroprotective response.
• GDNF modulates microglial activities, connecting this GO term to neuroinflammatory pathways.
• Pharmacological induction of GDNF, for example by catalpol, attenuates MPTP-induced degeneration of the nigral-striatal dopaminergic pathway in mice.
• Transcranial alternating current stimulation rescues motor deficits in a Parkinson's disease mouse model via GDNF production.
• AAV-mediated GDNF expression can be controlled by an improved Tet-on trans-activator, enabling tunable positive regulation.
• GDNF and its receptors are expressed during reinnervation after recurrent laryngeal nerve injury, linking this process to peripheral nerve regeneration.
• The GDNF 5'-untranslated region regulates expression at both transcriptional and translational levels, making it a model for multi-layer positive regulation.
• Astrocyte-derived neurotrophic support, including GDNF-related pathways, is a target for neuroprotective strategies in ischemic injury.
• GO:1900168 provides a standardized annotation for comparing diverse GDNF-inducing interventions across experimental systems [2, 3, 6].
What Happens During positive regulation of glial cell-derived neurotrophic factor production?
Transcriptional activation of the GDNF gene
In simple terms: The cell receives a signal that tells the GDNF gene to make more mRNA.
Positive regulation of GDNF production begins with increased transcription of the GDNF gene. The 5'-untranslated region of the mouse GDNF gene has been shown to regulate expression at the transcriptional level, indicating that promoter and upstream regulatory elements are key control points. Ischemic injury in the brain can trigger such transcriptional activation, as transient forebrain ischemia in rats induces GDNF expression. Pharmacological agents like catalpol also elevate GDNF levels in the striatum, consistent with transcriptional or post-transcriptional upregulation.
Translational control and mRNA stability
In simple terms: Even after mRNA is made, the cell can decide how much protein to produce from it.
The GDNF 5'-untranslated region also regulates expression at the translational level, meaning that positive regulation can occur after transcription by enhancing translation efficiency or mRNA stability. This dual-layer control allows cells to fine-tune GDNF output in response to physiological demand. Experimental systems such as AAV-mediated expression with a Tet-on trans-activator demonstrate that GDNF production can be exogenously controlled at the level of gene expression.
Stimulus-induced upregulation in the nervous system
In simple terms: Injuries or stimulation can switch on GDNF production as a protective response.
Transient forebrain ischemia in rats induces GDNF expression, showing that pathological stimuli can positively regulate this process in vivo. Transcranial alternating current stimulation rescues motor deficits in a Parkinson's disease mouse model via the production of GDNF, demonstrating that external neuromodulation can drive this GO term. These examples illustrate that positive regulation of GDNF production is an inducible, context-dependent process.
Pharmacological and genetic enhancement of GDNF levels
In simple terms: Drugs or gene therapy can push GDNF production higher.
Catalpol attenuates MPTP-induced neuronal degeneration of the nigral-striatal dopaminergic pathway in mice through elevating GDNF in the striatum, providing evidence that small molecules can positively regulate GDNF production. AAV-mediated GDNF expression using an improved Tet-on trans-activator allows controlled induction of GDNF, offering a genetic means to study positive regulation. These approaches are central to experimental work on GO:1900168.
Functional consequences for neurons and glia
In simple terms: More GDNF changes how neurons and glial cells behave.
GDNF regulates microglial activities, indicating that positive regulation of GDNF production can influence neuroinflammatory responses. In the context of peripheral nerve injury, trophic factor receptors are expressed during reinnervation after recurrent laryngeal nerve injury, linking GDNF signaling to regenerative processes. Astrocyte-derived neurotrophic support, including BDNF production, has been shown to exert neuroprotective effects during ischemic injury, highlighting the broader trophic factor network in which GDNF operates.
Key Genes Involved in GO:1900168 positive regulation of glial cell-derived neurotrophic factor production
The following genes and proteins are experimentally linked to positive regulation of GDNF production or to the downstream effects of this process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GDNF | Encodes glial cell-derived neurotrophic factor; its production is the target of GO:1900168 | Central to neuroprotection and Parkinson's disease research [2, 6] |
| GFRA1 | GDNF family receptor alpha-1; mediates GDNF signaling | Receptor expression studied during reinnervation after nerve injury |
| RET | Receptor tyrosine kinase that transduces GDNF signals | Key signaling node downstream of GDNF production |
| BDNF | Brain-derived neurotrophic factor; related neurotrophic factor | Astrocyte-derived BDNF is neuroprotective in ischemic injury |
| TH | Tyrosine hydroxylase; marker of dopaminergic neurons | Used to assess nigral-striatal dopaminergic pathway integrity in GDNF studies |
| DAT | Dopamine transporter; dopaminergic neuron marker | Evaluated in MPTP models with elevated GDNF |
| Iba1 | Microglial marker | Used to study GDNF effects on microglial activities |
| GFAP | Astrocyte marker | Relevant to astrocytic trophic factor production |
| NEFL | Neurofilament light chain; neuronal structural protein | Potential readout of neurotrophic support |
| CHAT | Choline acetyltransferase; motor neuron marker | Relevant to reinnervation after recurrent laryngeal nerve injury |
| SOD1 | Superoxide dismutase 1; oxidative stress marker | May be modulated by GDNF-mediated neuroprotection |
| CASP3 | Caspase-3; apoptosis effector | Used to assess neuronal degeneration in GDNF studies |
| TET | Tet-on trans-activator system component | Enables controlled AAV-mediated GDNF expression |
| AAV | Adeno-associated virus vector | Used for GDNF gene delivery and regulation |
| MPTP | Neurotoxin used to model Parkinson's disease | Catalpol-induced GDNF elevation protects against MPTP toxicity |
| 5'-UTR | 5' untranslated region of GDNF mRNA | Regulates GDNF expression at transcriptional and translational levels |
How Is positive regulation of glial cell-derived neurotrophic factor production Regulated?
Positive regulation of GDNF production is controlled at multiple levels. The GDNF 5'-untranslated region regulates expression at both transcriptional and translational levels, providing a built-in mechanism for fine-tuning protein output. Ischemic injury induces GDNF expression in the brain, indicating that pathological stimuli can activate this process. Pharmacological agents such as catalpol elevate GDNF in the striatum, likely through upstream signaling that converges on GDNF gene expression. Transcranial alternating current stimulation increases GDNF production in a Parkinson's disease model, showing that neuromodulation can regulate this process. AAV-mediated expression with a Tet-on trans-activator demonstrates that GDNF production can be exogenously controlled, offering a tool to dissect regulatory mechanisms. GDNF also regulates microglial activities, suggesting feedback or paracrine regulation within the nervous system.
positive regulation of glial cell-derived neurotrophic factor production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GDNF | Parkinson's disease; dopaminergic neuron survival | MPTP mouse model with catalpol treatment |
| GDNF | Ischemic brain injury | Transient forebrain ischemia in rats |
| GDNF | Motor deficits in Parkinson's disease | Transcranial alternating current stimulation in mice |
| GDNF | Neuroinflammation; microglial regulation | Microglial activity assays |
| GDNF | Peripheral nerve reinnervation | Recurrent laryngeal nerve injury model |
Parkinson's disease
GDNF is a potent survival factor for midbrain dopaminergic neurons, and positive regulation of its production is a therapeutic strategy in Parkinson's disease models. Transcranial alternating current stimulation rescues motor deficits in a mouse model of Parkinson's disease via the production of GDNF. Catalpol attenuates MPTP-induced neuronal degeneration of the nigral-striatal dopaminergic pathway in mice through elevating GDNF in the striatum. These studies show that boosting GDNF production can protect dopaminergic neurons and improve motor function.
Ischemic brain injury
Transient forebrain ischemia in rats induces GDNF expression, suggesting that positive regulation of GDNF production is part of an endogenous neuroprotective response. Astrocyte-derived BDNF production exerts neuroprotective effects during ischemic injury, highlighting the broader role of trophic factor upregulation in stroke. Enhancing GDNF production may therefore be a viable approach to limit ischemic damage.
Neuroinflammation and microglial regulation
GDNF regulates microglial activities, linking positive regulation of GDNF production to neuroinflammatory processes. By modulating microglial behavior, increased GDNF levels may influence the progression of neurodegenerative and neuroinflammatory conditions. This connection expands the disease relevance of GO:1900168 beyond neuronal survival.
Peripheral nerve injury and reinnervation
Expression of trophic factors receptors during reinnervation after recurrent laryngeal nerve injury suggests that GDNF signaling is involved in peripheral nerve regeneration. Positive regulation of GDNF production could therefore support reinnervation and functional recovery after nerve damage. This makes GO:1900168 relevant to regenerative medicine beyond the central nervous system.
From positive regulation of glial cell-derived neurotrophic factor production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a candidate gene reduce GDNF production? | CRISPR knockout cell line or mouse model |
| Does a point mutation in the GDNF 5'-UTR alter translational control? | CRISPR point-mutation knock-in in neuronal cells |
| Can a tagged GDNF allele report real-time production? | Knock-in of fluorescent or epitope tag at the GDNF locus |
| Does overexpression of a transcription factor increase GDNF levels? | CRISPR overexpression or AAV-mediated delivery |
| Can pharmacological agents induce GDNF in vivo? | MPTP mouse model treated with catalpol |
| Does neuromodulation increase GDNF production? | Transcranial alternating current stimulation in mice |
How to Study the positive regulation of glial cell-derived neurotrophic factor production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RT-qPCR | GDNF mRNA levels | Assessing transcriptional upregulation |
| ELISA | GDNF protein concentration | Quantifying production in cells and tissues |
| Western blot | GDNF protein expression | Confirming increased production |
| RNA-seq | Global transcriptome changes | Identifying pathways that positively regulate GDNF |
| CRISPR knockout | Loss-of-function effects on GDNF production | Testing candidate regulatory genes |
| CRISPR knock-in | Tagged GDNF allele for tracking | Real-time monitoring of GDNF production |
| AAV-mediated expression | Controlled GDNF delivery | Studying positive regulation in vivo |
| Behavioral tests | Motor function recovery | Evaluating neuroprotective effects of GDNF |
Gene expression analysis
Quantitative RT-PCR and RNA-seq can measure GDNF mRNA levels to assess transcriptional positive regulation. The 5'-untranslated region of GDNF regulates expression at both transcriptional and translational levels, so combining mRNA and protein measurements is essential. Ischemic injury studies have used such approaches to detect GDNF induction in the brain.
Protein quantification
ELISA and Western blot are standard methods to quantify GDNF protein levels in cells and tissues. Catalpol-induced elevation of GDNF in the striatum was demonstrated using protein-level assays. These methods are critical for confirming that positive regulation leads to increased functional protein.
CRISPR-based genetic models
CRISPR knockout, point mutation, and knock-in models allow causal testing of genes hypothesized to regulate GDNF production. AAV-mediated GDNF expression with a Tet-on trans-activator provides an inducible system to study positive regulation. These tools enable precise dissection of the regulatory network.
In vivo neuroprotection assays
Animal models of Parkinson's disease, ischemia, and nerve injury are used to test whether enhancing GDNF production improves outcomes. Transcranial alternating current stimulation rescues motor deficits via GDNF production, and catalpol protects dopaminergic neurons through GDNF elevation. Behavioral and histological readouts complement molecular analyses.
How CRISPR Can Be Used to Study GO:1900168 positive regulation of glial cell-derived neurotrophic factor production
Knockout
CRISPR knockout of candidate genes can determine whether they are required for positive regulation of GDNF production. For example, knocking out a transcription factor suspected to drive GDNF expression would test its necessity. This approach is foundational for causal inference in GO:1900168 research.
Point Mutation
Point mutations can be introduced into regulatory elements such as the GDNF 5'-untranslated region to dissect translational control mechanisms. CRISPR point-mutation models allow precise testing of how specific nucleotides affect GDNF production. This is particularly useful for understanding multi-layer regulation.
Knock-in
Knock-in of fluorescent or epitope tags at the GDNF locus enables real-time tracking of GDNF production in live cells. This approach can be combined with inducible systems like Tet-on to control expression. Tagged knock-in models are valuable for high-content screening of positive regulators.
Overexpression
CRISPR overexpression or AAV-mediated delivery can elevate GDNF levels to study downstream effects and neuroprotection. Overexpression models are useful for testing whether increased GDNF production is sufficient to rescue disease phenotypes, as seen in Parkinson's disease models [2, 6].
How EDITGENE Supports positive regulation of glial cell-derived neurotrophic factor production Research
Researchers studying positive regulation of glial cell-derived neurotrophic factor production-related genes often need to determine whether a candidate gene is causally involved in GDNF upregulation or whether it is merely correlated with increased GDNF levels. CRISPR-based models provide the gold standard for such causal tests, enabling knockout, point mutation, knock-in, and overexpression in relevant neuronal and glial cell types.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of glial cell-derived neurotrophic factor production research.
Frequently Asked Questions About positive regulation of glial cell-derived neurotrophic factor production
What is GO:1900168?
GO:1900168 is a Gene Ontology biological process term for positive regulation of glial cell-derived neurotrophic factor production, meaning any process that increases the frequency, rate, or extent of GDNF production.
What genes are involved in positive regulation of GDNF production?
Key genes include GDNF itself, its receptors GFRA1 and RET, and factors such as BDNF that influence neurotrophic support [5, 8]. The GDNF 5'-untranslated region also plays a regulatory role.
How is GDNF production regulated?
GDNF production is regulated at both transcriptional and translational levels, partly through its 5'-untranslated region. It can be induced by ischemic injury, pharmacological agents like catalpol, and electrical stimulation.
What diseases are linked to GDNF production?
GDNF production is linked to Parkinson's disease [2, 6], ischemic brain injury, neuroinflammation, and peripheral nerve reinnervation.
Can CRISPR be used to study GDNF regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test causal roles of genes in GDNF production. AAV-mediated systems with Tet-on trans-activators also allow controlled expression.
What is the role of GDNF in Parkinson's disease?
GDNF supports the survival of midbrain dopaminergic neurons, and increasing its production rescues motor deficits in Parkinson's disease models [2, 6].
How does catalpol affect GDNF?
Catalpol attenuates MPTP-induced neuronal degeneration of the nigral-striatal dopaminergic pathway in mice through elevating GDNF in the striatum.
Does transcranial alternating current stimulation increase GDNF?
Yes, transcranial alternating current stimulation rescues motor deficits in a mouse model of Parkinson's disease via the production of GDNF.
What is the 5'-untranslated region of GDNF?
The 5'-untranslated region of the mouse GDNF gene regulates expression at both transcriptional and translational levels, making it a key control element for GDNF production.
How does GDNF affect microglia?
GDNF regulates microglial activities, linking positive regulation of GDNF production to neuroinflammatory processes.
Conclusion
GO:1900168, positive regulation of glial cell-derived neurotrophic factor production, is a biologically and clinically significant process that governs the availability of a major neurotrophic factor. Its regulation occurs at multiple levels, from transcription to translation, and can be enhanced by pharmacological, electrical, and genetic interventions [2, 3, 6, 7]. The term is directly relevant to Parkinson's disease, ischemic injury, neuroinflammation, and peripheral nerve regeneration [1, 2, 4, 8]. By combining CRISPR-based causal models with quantitative expression and protein assays, researchers can systematically dissect the pathways that positively regulate GDNF production and translate these findings into neuroprotective therapies.
References
- 1. Chang YP et al.. 2006. Regulation of microglial activities by glial cell line derived neurotrophic factor.. J Cell Biochem 97(3):501-11 PMID: 16187294
- 2. Lee HJ et al.. 2022. Transcranial alternating current stimulation rescues motor deficits in a mouse model of Parkinson's disease via the production of glial cell line-derived neurotrophic factor.. Brain Stimul 15(3):645-653 PMID: 35429660
- 3. Chen T et al.. 2005. [Regulation of AAV-mediated glial cell-line derived neurotrophic factor expression by using improved Tet-on trans-activator].. Zhonghua Yi Xue Za Zhi 85(6):405-8 PMID: 15854532
- 4. Miyazaki H et al.. 2001. Expression of glial cell line-derived neurotrophic factor induced by transient forebrain ischemia in rats.. Brain Res 922(2):165-72 PMID: 11743946
- 5. Yuan L et al.. 2016. 14,15-epoxyeicosatrienoic acid promotes production of brain derived neurotrophic factor from astrocytes and exerts neuroprotective effects during ischaemic injury.. Neuropathol Appl Neurobiol 42(7):607-620 PMID: 26526810
- 6. Xu G et al.. 2010. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.. Neuroscience 167(1):174-84 PMID: 20123001
- 7. Tanaka M et al.. 2001. The 5'-untranslated region of the mouse glial cell line-derived neurotrophic factor gene regulates expression at both the transcriptional and translational levels.. Brain Res Mol Brain Res 91(1-2):81-95 PMID: 11457495
- 8. Hernandez-Morato I et al.. 2019. Expression of trophic factors receptors during reinnervation after recurrent laryngeal nerve injury.. Laryngoscope 129(11):2537-2542 PMID: 30811036
